All articles
Tirzepatide Side Effects: Causes & Management
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Importance of Medical Consultation When Taking Tirzepatide
Given the potential for significant side effects and specific contraindications, treatment with Tirzepatide should always be provided with the guidance of a licensed medical provider. Consulting healthcare providers is crucial for:
Conducting a thorough medical evaluation to determine suitability.
Personalizing dosing while considering existing medications and health conditions.
Regularly reviewing treatment progress and any adverse effects experienced.
Get Personalized Guidance With Mochi Health
Mochi Health is a pivotal resource for individuals considering Tirzepatide for weight management. Offering 1-on-1 support from licensed physicians and personalized treatment plans, Mochi Health ensures that patients not only understand the nuances of Tirzepatide treatment but also receive comprehensive care tailored to their health goals.
Check out Mochi Health to get personalized guidance on whether Tirzepatide is right for you and to explore personalized treatment options. Our team is dedicated to supporting your health and wellness journey with the latest in medical treatment innovations and dedicated provider support.
References:
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://europepmc.org/article/pmc/pmc7526454
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 398(10295), 143–155 https://pubmed.ncbi.nlm.nih.gov/34186022/
MOUNJAROTM (Tirzepatide) Injection, for Subcutaneous Use.” Access Data FDA, Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of clinical medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















